Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Selective Capture and Determination of Receptor-Binding Hemagglutinin in Influenza Vaccine Preparations Using a Coupled Receptor-Binding/RP-HPLC Assay.

Lorbetskie B, Cunningham AM, Lemieux M, Durno L, Farnsworth A, Wang J, Li C, Li X, Gilbert M, Sauvé S, Girard M.

Anal Chem. 2019 Jul 16;91(14):8908-8917. doi: 10.1021/acs.analchem.9b00617. Epub 2019 Jun 28.

PMID:
31251585
2.

Conformationally selective biophysical assay for influenza vaccine potency determination.

Wen Y, Han L, Palladino G, Ferrari A, Xie Y, Carfi A, Dormitzer PR, Settembre EC.

Vaccine. 2015 Oct 5;33(41):5342-5349. doi: 10.1016/j.vaccine.2015.08.077. Epub 2015 Sep 6.

PMID:
26348403
3.

Trypsin pre-treatment corrects SRID over-estimation of immunologically active, pre-fusion HA caused by mixed immunoprecipitin rings.

Wen Y, Palladino G, Xie Y, Ferrari A, Ma X, Han L, Dormitzer PR, Settembre EC.

Vaccine. 2016 Jun 17;34(29):3388-95. doi: 10.1016/j.vaccine.2016.04.091. Epub 2016 May 4.

PMID:
27154389
4.

A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.

Schmeisser F, Jing X, Joshi M, Vasudevan A, Soto J, Li X, Choudhary A, Baichoo N, Resnick J, Ye Z, McCormick W, Weir JP.

Influenza Other Respir Viruses. 2016 Mar;10(2):134-40. doi: 10.1111/irv.12365. Epub 2016 Jan 29.

5.

Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity.

Wen Y, Palladino G, Xie Y, Ferrari A, Settembre EC.

Vaccine. 2018 May 17;36(21):3010-3017. doi: 10.1016/j.vaccine.2018.04.021. Epub 2018 Apr 19.

PMID:
29680201
6.

Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays.

Lorbetskie B, Wang J, Gravel C, Allen C, Walsh M, Rinfret A, Li X, Girard M.

Vaccine. 2011 Apr 18;29(18):3377-89. doi: 10.1016/j.vaccine.2011.02.090. Epub 2011 Mar 11.

PMID:
21397719
7.

Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination.

Morgenstern K, Xie Y, Palladino G, Barr JR, Settembre EC, Williams TL, Wen Y.

Vaccine. 2018 Oct 1;36(41):6144-6151. doi: 10.1016/j.vaccine.2018.08.065. Epub 2018 Sep 5.

8.

An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.

Schmeisser F, Vodeiko GM, Lugovtsev VY, Stout RR, Weir JP.

Vaccine. 2010 Mar 11;28(12):2442-9. doi: 10.1016/j.vaccine.2009.12.079. Epub 2010 Jan 12.

PMID:
20074687
9.

Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.

Verma S, Soto J, Vasudevan A, Schmeisser F, Alvarado-Facundo E, Wang W, Weiss CD, Weir JP.

PLoS One. 2017 Apr 19;12(4):e0175733. doi: 10.1371/journal.pone.0175733. eCollection 2017.

10.

Fast and highly selective determination of hemagglutinin content in quadrivalent influenza vaccine by reversed-phase high-performance liquid chromatography method.

Lorbetskie B, Fortin N, Durno L, Wang J, Li C, Li X, Girard M, Sauvé S.

J Chromatogr A. 2017 Dec 15;1528:18-24. doi: 10.1016/j.chroma.2017.10.041. Epub 2017 Oct 18.

PMID:
29122283
11.

A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines.

Schmeisser F, Vasudevan A, Soto J, Kumar A, Williams O, Weir JP.

Influenza Other Respir Viruses. 2014 Sep;8(5):587-95. doi: 10.1111/irv.12272. Epub 2014 Aug 2.

12.

Evaluation of Haemagglutinin Content by RP-HPLC to Generate Pandemic Influenza Vaccine.

Kang H, Roh HS, Song H, Lee K, Chung ST, Ban SJ, Mo IP, An BS, Ahn CY.

Toxicol Res. 2016 Oct;32(4):269-274. Epub 2016 Oct 30.

13.

Potency determination of inactivated H7 influenza vaccines using monoclonal antibody-based ELISA and biolayer interferometry assays.

Vasudevan A, Woerner A, Schmeisser F, Verma S, Williams O, Weir JP.

Influenza Other Respir Viruses. 2018 Mar;12(2):250-258. doi: 10.1111/irv.12528. Epub 2017 Dec 15.

14.

The differential effect of sub-micron level HA aggregates on influenza potency assays.

Lemieux M, Lorbetskie B, Luebbert CC, Walrond L, Li C, Li X, Cyr T, Sauvé S, Johnston MJW, Farnsworth A.

Vaccine. 2019 Aug 23;37(36):5276-5287. doi: 10.1016/j.vaccine.2019.07.050. Epub 2019 Jul 20.

PMID:
31337591
15.

Critical review of current and emerging quantification methods for the development of influenza vaccine candidates.

Manceur AP, Kamen AA.

Vaccine. 2015 Nov 4;33(44):5913-9. doi: 10.1016/j.vaccine.2015.07.104. Epub 2015 Aug 10. Review.

PMID:
26271833
16.

Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza.

Vodeiko GM, Weir JP.

Influenza Other Respir Viruses. 2012 May;6(3):176-87. doi: 10.1111/j.1750-2659.2011.00285.x. Epub 2011 Sep 8.

17.

Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.

Khurana S, King LR, Manischewitz J, Coyle EM, Golding H.

Vaccine. 2014 Apr 17;32(19):2188-97. doi: 10.1016/j.vaccine.2014.02.049. Epub 2014 Mar 6.

PMID:
24613520
18.

Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine.

Li C, Xu K, Hashem A, Shao M, Liu S, Zou Y, Gao Q, Zhang Y, Yuan L, Xu M, Li X, Wang J.

Hum Vaccin Immunother. 2015;11(6):1351-6. doi: 10.1080/21645515.2015.1032490.

19.

A novel synthetic receptor-based immunoassay for influenza vaccine quantification.

Hashem AM, Gravel C, Farnsworth A, Zou W, Lemieux M, Xu K, Li C, Wang J, Goneau MF, Merziotis M, He R, Gilbert M, Li X.

PLoS One. 2013;8(2):e55428. doi: 10.1371/journal.pone.0055428. Epub 2013 Feb 12.

20.

Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay.

Chae W, Kim P, Hwang BJ, Seong BL.

Vaccine. 2019 Mar 7;37(11):1457-1466. doi: 10.1016/j.vaccine.2019.01.068. Epub 2019 Feb 11.

Supplemental Content

Support Center